Potential Perinatally Acquired Extended Spectrum β-Lactamase Escherichia coli Urinary Tract Infection in an Infant

Area of Science:

• Microbiology
• Infectious Diseases
• Pediatrics

Background:

• Extended-spectrum β-lactamases (ESBL) confer resistance to β-lactam antibiotics, complicating treatment of Enterobacteriaceae infections.
• ESBL infections are associated with poor outcomes, increased complications, and mortality, particularly in critically ill patients.
• Limited guidelines exist for managing ESBL-producing organisms in pediatric populations, necessitating further research.

Observation:

• A case report details an 8-month-old female infant diagnosed with a urinary tract infection.
• The infection was caused by multidrug-resistant, ESBL-producing Escherichia coli.
• The infant had no typical risk factors associated with ESBL-producing organisms.

Findings:

• The infant's ESBL-producing E. coli urinary tract infection was successfully treated with sulfamethoxazole/trimethoprim.
• This non-β-lactam therapy demonstrated effectiveness in a pediatric case.
• The successful treatment challenges the assumption that carbapenems are the sole option for ESBL infections.

Implications:

• This case highlights the potential utility of sulfamethoxazole/trimethoprim for treating ESBL-producing E. coli infections in pediatric patients.
• It underscores the need for further investigation into alternative antimicrobial therapies for multidrug-resistant infections in children.
• Findings may inform the development of more tailored empiric antimicrobial strategies for pediatric patients, especially those without traditional risk factors.